Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence

Autor: Linder, Simon, Hoogstraat, Marlous, Stelloo, Suzan, Eickhoff, Nils, Schuurman, Karianne, de Barros, Hilda, Alkemade, Maartje, Bekers, Elise M., Severson, Tesa M., Sanders, Joyce, Huang, Chia Chi Flora, Morova, Tunc, Altintas, Umut Berkay, Hoekman, Liesbeth, Kim, Yongsoo, Baca, Sylvan C., Sjöström, Martin, Zaalberg, Anniek, Hintzen, Dorine C., de Jong, Jeroen, Kluin, Roelof J.C., de Rink, Iris, Giambartolomei, Claudia, Seo, Ji Heui, Pasaniuc, Bogdan, Altelaar, Maarten, Medema, René H., Feng, Felix Y., Zoubeidi, Amina, Freedman, Matthew L., Wessels, Lodewyk F.A., Butler, Lisa M., Lack, Nathan A., van der Poel, Henk, Bergman, Andries M., Zwart, Wilbert, Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics
Přispěvatelé: Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Chemical Biology, Pathology, CCA - Cancer biology and immunology, Ethics, Law & Medical humanities, APH - Quality of Care, Urology
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Urologic Diseases
Epigenomics
Male
Aging
Oncology and Carcinogenesis
ARNTL Transcription Factors/genetics
Drug Resistance
Drug Resistance
Neoplasm/genetics

SDG 3 – Goede gezondheid en welzijn
Castration-Resistant
Article
Cell Line
Androgen
SDG 3 - Good Health and Well-being
Cell Line
Tumor

Receptors
Nitriles
Phenylthiohydantoin
Taverne
2.1 Biological and endogenous factors
Humans
Aetiology
Androgens/pharmacology
Cancer
Prostatic Neoplasms
Castration-Resistant/drug therapy

Castration-Resistant/drug therapy
Tumor
Nitriles/therapeutic use
Neoplasm/genetics
Prostate Cancer
Aryl Hydrocarbon Receptor Nuclear Translocator
Androgen/genetics
Prostatic Neoplasms
ARNTL Transcription Factors
Receptors
Androgen/genetics

Circadian Rhythm
Prostatic Neoplasms
Castration-Resistant

Oncology
5.1 Pharmaceuticals
Drug Resistance
Neoplasm

Receptors
Androgen

Benzamides
Androgens
Neoplasm
Development of treatments and therapeutic interventions
Biotechnology
Zdroj: Cancer Discovery, 12(9), 2074-2097. American Association for Cancer Research Inc.
Cancer Discovery, 12(9), 2074. American Association for Cancer Research Inc.
Linder, S, Hoogstraat, M, Stelloo, S, Eickhoff, N, Schuurman, K, de Barros, H, Alkemade, M, Bekers, E M, Severson, T M, Sanders, J, Huang, C-C F, Morova, T, Altintas, U B, Hoekman, L, Kim, Y, Baca, S C, Sjöström, M, Zaalberg, A, Hintzen, D C, de Jong, J, Kluin, R J C, de Rink, I, Giambartolomei, C, Seo, J-H, Pasaniuc, B, Altelaar, M, Medema, R H, Feng, F Y, Zoubeidi, A, Freedman, M L, Wessels, L F A, Butler, L M, Lack, N A, van der Poel, H, Bergman, A M & Zwart, W 2022, ' Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence ', Cancer discovery, vol. 12, no. 9, pp. 2074-2097 . https://doi.org/10.1158/2159-8290.CD-21-0576
Cancer Discov
Cancer discovery, 12(9)
Cancer discovery, vol 12, iss 9
Cancer discovery, 12(9), 2074-2097. American Association for Cancer Research Inc.
ISSN: 2159-8274
DOI: 10.1158/2159-8290.cd-21-0576
Popis: In prostate cancer, androgen receptor (AR)–targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients’ clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target. Significance: Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development. See related commentary by Zhang et al., p. 2017. This article is highlighted in the In This Issue feature, p. 2007
Databáze: OpenAIRE